M. Brent

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial

B. Escudier, S. Oosting, S. Bracarda, 2020 .